Pédiatrique divers

  • Accueil
  • Pédiatrique divers
  • DIPG HRQOL

TITRE (EN) Health Related Quality of Life (HRQL) and Symptom Assessment in Patients Diagnosed With Diffuse Intrinsic Pontine Glioma (DIPG) or Recurrent and Re-irradiated Brain Tumours and Their Caregivers: A Non-Therapeutic Study
PROTOCOLE ID DIPG HRQOL
CLINICAL TRIAL.gov ID NCT04670016
TYPE(S) DE CANCER Pédiatrique divers
PHASE Autres
TYPE D'ÉTUDE Autre
INSTITUTION CHU DE QUEBEC
2705 boulevard Laurier
(418) 525-4444
VILLE Québec
INVESTIGATEUR(RICE) PRINCIPAL(E) Valérie Larouche
COORDONATEUR(RICE) Panagiota Giannakouros
panagiota.giannak@crchudequebec.ulaval.ca
418-525-4444 poste 40121
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Patient aged >2 and <21 years treated with a repeat course of radiation for DIPG or other recurrent or progressive brain tumour.
  • Radiation for the first tumour must be a primary brain neoplasm (i.e. not leukemia).
  • Enrollment within 14 days of starting re-irradiation (RT2).
  • Patients with malignant transformation of the first tumour are eligible.
  • There are no restrictions on histology or RT1/RT2 dose-fractionation or RT2 body site. In other words, RT2 may be directed at a different location to RT1.
  • The patient is treated at a site where the study is approved by the local ethics board
  • Consent, and, if applicable, assent, has been obtained according to institutional standards
CRITÈRES D'EXCLUSION (EN)
  • Inability to complete questionnaires in English or French.